We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Drug Causing Severe Side Effects Is Withdrawn

By HospiMedica staff writers
Posted on 15 Dec 2000
A prescription medication approved to treat irritable bowel syndrome (IBS) in women has been voluntarily withdrawn from the market by the manufacturer at the request of the U.S. More...
Food and Drug Administration (FDA). The drug, alosetron hydrochloride (Lotronex), is the product of Glaxo Wellcome (London, UK).

The company's action followed an analysis by the U.S. Food and Drug Administration (FDA) of reports of serious side effects since the drug's approval in February, including the deaths of five patients. Other side effects that were reported included 49 cases of ischemic colitis and 21 cases of severe constipation. In all, 34 cases resulted in hospitalization.

Following its analysis, the FDA met with Glaxo Wellcome to consider a number of marketing options, including restricting distribution of the drug or market withdrawal. At the conclusion of the meeting, Glaxo informed the FDA that it would voluntarily withdraw the drug. In the meantime, the FDA is advising patients taking the drug to contact their healthcare providers in order to discuss alternative treatments.



Related Links:
FDA
Glaxo Wellcome

Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
New
Radiology Monitor
Barco MDNC-12130 Nio Fusion 12MP Radiology Monitor
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.